We assessed the effect of sotorasib alone or in combination with DT2216 (a clinical-stage BCL-X<sub>L</sub> proteolysis targeting chimera [PROTAC]) on KRAS<sup>G12C</sup>-mutated NSCLC, CRC and pancreatic cancer (PC) cell lines using MTS cell viability, colony formation and Annexin-V/PI apoptosis assays. This evidence concerns the gene KRAS and pancreatic neoplasm.